Comparison of Pola-R-CHP and R-CHOP for newly diagnosed DLBCL: A single-center retrospective study
{{output}}
Background Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisolone (Pola-R-CHP) has become a first-line treatment option for diffuse large B-cell lymphoma (DLBCL), but real-world data remain limited. We retrospectively compared Pola... ...
